文献速递心血管MR

人重组腺苷三磷酸双磷酸水解酶治疗保护大鼠心肌缺血再灌注损伤并保留左心室收缩功能:7T心血管磁共振成像评价

Human Recombinant Apyrase Therapy Protects Against Myocardial Ischemia/Reperfusion Injury and Preserves Left Ventricular Systolic Function in Rats, as Evaluated by 7T Cardiovascular Magnetic Resonance Imaging.
PubMed 文献 · Korean J Radiol · 2020-01-01

研究将54只左前降支结扎60分钟致心肌梗死的大鼠随机分为APT102组(n=27)与对照组(n=27),于再灌注前15分钟及再灌注后24、48、72小时和第4天静脉输注APT102(0.3 mg/kg)或安慰剂,用7T心血管磁共振在再灌注后24、48、72小时和第5天评价。结果显示APT102组梗死范围、水肿、IMH和MVO均较对照组轻,LVEF较高;IMH在再灌注后48小时达峰值,且IMH与MVO正相关、与LVEF负相关。

要点

  • 7T CMR可在急性期动态显示IMH与MVO演变,IMH于再灌注后48小时达峰值。
  • APT102组梗死范围、水肿、IMH、MVO均较对照组减轻,LVEF较对照组高。
  • IMH与MVO正相关(r=0.392,p<0.001),与LVEF负相关(r=-0.294,p=0.010)。

核心结论

  • APT102可显著减轻缺血心肌和微血管的损伤。
  • IMH范围在再灌注后48小时达峰值,IMH是MVO的下游结果。
  • IMH可能是预防心肌梗死后不良重构的潜在治疗靶点。

研究设计与样本

  • 动物实验:54只左前降支起始部结扎60分钟致心肌梗死的大鼠,随机分为APT102组(n=27)和对照组(n=27)。
  • 再灌注前15分钟及再灌注后24、48、72小时和第4天静脉输注APT102(0.3 mg/kg)或安慰剂。
  • 再灌注后24、48、72小时和第5天用7T系统行CMRI,随后取心脏行组织病理学检查。
  • cine成像定量心功能,T2 mapping评价IMH/水肿,晚期钆增强评价梗死/MVO。

关键影像表现/征象

  • APT102组梗死范围(p<0.001)、水肿(p<0.001)、IMH(p=0.013)和MVO(p=0.049)均较对照组轻。
  • 再灌注后48小时的IMH范围显著大于24小时、72小时和5天(均p<0.001)。
  • APT102组LVEF显著高于对照组(p=0.006)。
  • LVEF与IMH呈负相关(r=-0.294,p=0.010),IMH与MVO呈正相关(r=0.392,p<0.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: The occurrence of intramyocardial hemorrhage (IMH) and microvascular obstruction (MVO) in myocardial infarction (MI), known as severe ischemia/reperfusion injury (IRI), has been associated with adverse remodeling. APT102, a soluble human recombinant ecto-nucleoside triphosphate diphosphohydrolase-1, can hydrolyze extracellular nucleotides to attenuate their prothrombotic and proinflammatory effects. The purpose of this study was to temporally evaluate the therapeutic effect of APT102 on IRI in rats and to elucidate the evolution of IRI in the acute stage using cardiovascular magnetic resonance imaging (CMRI).

MATERIALS AND METHODS: Fifty-four rats with MI, induced by ligation of the origin of the left anterior descending coronary artery for 60 minutes, were randomly divided into the APT102 (n = 27) or control (n = 27) group. Intravenous infusion of APT102 (0.3 mg/kg) or placebo was administered 15 minutes before reperfusion, and then 24 hours, 48 hours, 72 hours, and on day 4 after reperfusion. CMRI was performed at 24 hours, 48 hours, 72 hours, and on day 5 post-reperfusion using a 7T system and the hearts were collected for histopathological examination. Cardiac function was quantified using cine imaging and IMH/edema using T2 mapping, and infarct/MVO using late gadolinium enhancement.

RESULTS: The extent of infarction (p < 0.001), edema (p < 0.001), IMH (p = 0.013), and MVO (p = 0.049) was less severe in the APT102 group than in the control group. IMH size at 48 hours was significantly greater than that at 24 hours, 72 hours, and 5 days after reperfusion (all p < 0.001). The left ventricular ejection fraction (LVEF) was significantly greater in the APT102 group than in the control group (p = 0.006). There was a negative correlation between LVEF and IMH (r = -0.294, p = 0.010) and a positive correlation between IMH and MVO (r = 0.392, p < 0.001).

CONCLUSION: APT102 can significantly alleviate damage to the ischemic myocardium and microvasculature. IMH size peaked at 48 hours post reperfusion and IMH is a downstream consequence of MVO. IMH may be a potential therapeutic target to prevent adverse remodeling in MI.

来源:Korean J Radiol,查看原文。版权归原作者所有。

引用

  1. Xu Z, Chen W, Zhang R, et al. Human Recombinant Apyrase Therapy Protects Against Myocardial Ischemia/Reperfusion Injury and Preserves Left Ventricular Systolic Function in Rats, as Evaluated by 7T Cardiovascular Magnetic Resonance Imaging. Korean J Radiol. 2020. PMID: 32410404. doi:10.3348/kjr.2019.0853

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。